Recent advances in oxazolidinones as antituberculosis agents.
Haijia LuHuahao WangHongyi ZhaoDongfeng ZhangPublished in: Future medicinal chemistry (2022)
Tuberculosis (TB) is an infectious and fatal disease caused by Mycobacterium tuberculosis ( Mtb ) and remains a serious public health threat; therefore, the development of new antitubercular agents is a priority for the World Health Organization's End TB strategy and the United Nations' Sustainable Development Goals to eradicate TB. Oxazolidinones are a class of synthetic antibacterial agents with a distinct mode of action developed for the treatment of Gram-positive bacterial infections. Many oxazolidinones exhibit good activity against Mtb , and some are currently in clinical trials for multidrug-resistant TB and extensively drug-resistant TB therapy. In this review, the mechanism of action, activity and toxicity of oxazolidinones and recent progress in the research and development of oxazolidinones as anti-TB agents are summarized.
Keyphrases
- mycobacterium tuberculosis
- multidrug resistant
- drug resistant
- pulmonary tuberculosis
- gram negative
- public health
- acinetobacter baumannii
- clinical trial
- stem cells
- oxidative stress
- randomized controlled trial
- hepatitis c virus
- mesenchymal stem cells
- escherichia coli
- bone marrow
- cystic fibrosis
- study protocol
- global health
- oxide nanoparticles
- replacement therapy